Antisense Oligonucleotide Drugs for Duchenne Muscular Dystrophy: How Far Have We Come and What Does the Future Hold?

References

• Duchenne . The pathology of paralysis with muscular degeneration (paralysie myosclerotique), or paralysis with apparent hypertrophy. Br. Med. J.2 (363), 541–542 (1867).
   PubMedGoogle Scholar
• Koenig M , BeggsAH, MoyerMet al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet.45 (4), 498–506 (1989).
   PubMed Web of Science ®Google Scholar
• Hoffman EP , BrownRHJr, KunkelLM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell51 (6), 919–928 (1987).
   PubMed Web of Science ®Google Scholar
• Fenichel GM , FlorenceJM, PestronkAet al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology41 (12), 1874–1877 (1991).
   PubMed Web of Science ®Google Scholar
• Touznik A , LeeJJ, YokotaT. New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin. Biol. Ther.14 (6), 809–819 (2014).
   PubMed Web of Science ®Google Scholar
• Zamecnik PC , StephensonML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA75 (1), 280–284 (1978).
   PubMed Web of Science ®Google Scholar
• Torchilin VP . Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng.8343–375 (2006).
   PubMed Web of Science ®Google Scholar
• Muntoni F , WoodMJ. Targeting RNA to treat neuromuscular disease. Nat. Rev. Drug Discov.10 (8), 621–637 (2011).
   PubMed Web of Science ®Google Scholar
• Lee JJ , YokotaT. Antisense therapy in neurology. J. Pers. Med.3 (3), 144–176 (2013).
   PubMedGoogle Scholar
• Aartsma-Rus A , FokkemaI, VerschuurenJet al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat.30 (3), 293–299 (2009).
   PubMed Web of Science ®Google Scholar
• Echigoya Y , AokiY, MiskewBet al. Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45–55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol. Ther. Nucleic Acids4e225 (2015).
   PubMedGoogle Scholar
• van Deutekom JC , JansonAA, GinjaarIBet al. Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med.357 (26), 2677–2686 (2007).
   PubMed Web of Science ®Google Scholar
• Kinali M , Arechavala-GomezaV, FengLet al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol.8 (10), 918–928 (2009).
   PubMed Web of Science ®Google Scholar
• Cirak S , Arechavala-GomezaV, GuglieriMet al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, Phase 2, dose-escalation study. Lancet378 (9791), 595–605 (2011).
   PubMed Web of Science ®Google Scholar
• Goemans NM , TuliniusM, van den AkkerJTet al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med.364 (16), 1513–1522 (2011).
   PubMed Web of Science ®Google Scholar
• Lublin FD , ReingoldSC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology46 (4), 907–911 (1996).
   PubMed Web of Science ®Google Scholar
• Voit T , TopalogluH, StraubVet al. Safety and efficacy of drisapersen for the treatment of duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled Phase 2 study. Lancet Neurol.13 (10), 987–996 (2014).
   PubMed Web of Science ®Google Scholar
• Yokota T , LuQL, MorganJEet al. Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J. Cell Sci.119 (Pt 13), 2679–2687 (2006).
   PubMed Web of Science ®Google Scholar
• Echigoya Y , MoulyV, GarciaL, YokotaT, DuddyW. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy. PLoS ONE10 (3), e0120058 (2015).
   PubMed Web of Science ®Google Scholar
• Goyenvalle A , GriffithG, BabbsAet al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med.21 (3), 270–275 (2015).
   PubMed Web of Science ®Google Scholar